Clinical Trials

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

52 enrolled

Inflammatory Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

280 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02324088 2021-02-21

PEGASE07

Phase 3 Completed

174 enrolled

Inflammatory Breast Neoplasms

NCT02682693 2021-02-02

GeparX

780 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Phase 3 Unknown

290 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00820547 2019-10-22

Beverly1

100 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00513695 2019-08-07

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

68 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00499122 2018-01-02

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

41 enrolled 10 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00006110 2017-07-31

NRR

82 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase 3 Completed

961 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00182793 2017-02-23

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

32 enrolled 6 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2 Terminated

15 enrolled 10 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01880385 2013-06-19

Beva

Phase 1 Unknown

30 enrolled

Inflammatory Breast Neoplasms

NCT00072319 2013-03-04

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00005798 2012-10-26

CTC

209 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

Phase 2 Unknown

60 enrolled